A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV

A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV

Objectives. Filibuvir is a non-nucleoside inhibitor of hepatitis C virus (HCV) polymerase. This study evaluated the safety and efficacy of filibuvir plus pegylated interferon alfa-2a (pegIFN)/ribavirin.Material and methods. Treatment-naïve, HCV genotype-1 patients were randomized to receive filibuvi...

Full description

Bibliographic Details
Main Authors: Maribel Rodriguez-Torres, Eric M. Yoshida, Patrick Marcellin, Subasree Srinivasan, Vivek S. Purohit, Cunshan Wang, Jennifer L. Hammond, Ph.D.
Format: Article
Language:English
Published: Elsevier 2014-07-01
Series:Annals of Hepatology
Subjects:
NS5B
Non-nucleoside inhibitor
Treatment naïve
Safety
Efficacy
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119308439

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119308439

Similar Items